GLP-1 Drugs Surge in U.S. Obesity Fight | US News

Gallup’s latest data reveals a dramatic spike in U.S. adults using weight-loss GLP-1 drugs—now 11% of the population, up from just 3% a few years ago. These meds, including Ozempic and Wegovy, have become household names, with 91% of Americans aware of them and 15% having tried one. The surge coincides with a drop in national obesity rates and stabilized diabetes levels, suggesting real health impact. While brand-name drugs still dominate, 19% are opting for cheaper compounded versions due to cost or insurance issues—despite FDA warnings. Most users, regardless of version, report strong results. GLP-1s have reshaped obesity treatment in America, and with prices falling and more options emerging, this trend is far from slowing down—even as questions about insurance and long-term effects linger. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/595241c590ebd5f0